TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2025-03-04
余忠仁Yu, Chong-Jen
- 計畫主持人
- 執行臨床試驗年資 23 年 9 個月
發表文獻
116筆
111
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan A, Perez-Moreno P, Button P, Yang H, Ahn MJ, Mok T. First-line erlotinib until and beyond RECIST progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol 2016;2:305-12.
112
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao M, Zhu Y, Zhou C, Fuerte F, Margono B, Wen W, Tsai J, Truman M, Klughammer B, Shames DS, Wu L. Detection and dynamic changes of EGFR mutations from circulating tumour DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015;21:3196-203.
113
Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas M, Gabor EJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis B, Jain V. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC infectious diseases 2013;13:343.
114
Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, Yu CJ, Archer V , Magalie Hilton, Paul Delmar, Celine Pallaud, Martin Reck . A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC): results of the phase II randomized ABIGAIL study (BO21015) J Thorac Oncol 2014 ;9:848-55.
115
Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, Sun Y, Margono B, Fuerte F, Chang GC, Seetalarom K, Wang J, Cheng A, Syahruddin E, Qian X, Ho J, Kurnianda J, Liu HE, Jin K, Truman M, Bara I, Mok T. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double -blind trial. Lancet Oncol 2013;14:777-86.
116
Hwang SJ, Chang SC, Yu CJ, Chan YJ, Chen TJ, Hsieh SL, Lai HY, Lin MH, Liu JY, Ong G, Roman F, Dramé M, Bock HL, Yang PC. Immunogenicity and safety of an AS03A-adjuvanted H5N1 influenza vaccine in a Taiwanese population. J Formos Med Assoc. 2011;110:780-786.
